Sonia Gómez-Martínez

Dr. Sonia Gómez-Martínez

Immunonutrition Research Group, Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2016 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
NSNitin Shivappa
Nitin Shivappa
JHJames R. Hebert
James R. Hebert
AMAscensión Marcos
Ascensión Marcos
LDLigia‐Esperanza Diaz
Ligia‐Esperanza Diaz
SGSonia Gómez-Martínez
Sonia Gómez-Martínez
IHInge Huybrechts
Inge Huybrechts

15 June 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
NUNOEMI REDONDO USEROS
NOEMI REDONDO USEROS
EREsther Nova Rebato
Esther Nova Rebato
NGNatalia González-Zancada
Natalia González-Zancada
LPLigia Esperanza Díaz Prieto
Ligia Esperanza Díaz Prieto
SGSonia Gómez-Martínez
Sonia Gómez-Martínez
Ascensión MarcosAscensión Marcos
Ascensión Marcos
It is widely known that a good balance and healthy function for bacteria groups in the colon are necessary to maintain homeostasis and preserve health. However, the lack of consensus on what defines a healthy gut microbiota and the multitude of factors that influence human gut microbiota composition complicate the development of appropriate dietary recommendations for our gut microbiota. Furthermore, the varied response to the intake of probiotics and prebiotics observed in healthy adults suggests the existence of potential inter- and intra-individual factors, which might account for gut microbiota changes to a greater extent than diet. The changing dietary habits worldwide involving consumption of processed foods containing artificial ingredients, such as sweeteners; the coincident rise in emotional disorders; and the worsening of other lifestyle habits, such as smoking habits, drug consumption, and sleep, can together contribute to gut dysbiosis and health impairment, as well as the development of chronic diseases. This review summarizes the current literature on the effects of specific dietary ingredients (probiotics, prebiotics, alcohol, refined sugars and sweeteners, fats) in the gut microbiota of healthy adults and the potential inter- and intra-individual factors involved, as well as the influence of other potential lifestyle factors that are dramatically increasing nowadays.

7 July 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
EREsther Nova Rebato
Esther Nova Rebato
SGSonia Gómez-Martínez
Sonia Gómez-Martínez
Rocio Gonzalez SolteroRocio Gonzalez Soltero
Rocio Gonzalez Soltero
There is increasing evidence that diet influences the relationship between gut microbiota and individual health outcomes. Nutrient intake affects the composition of the gut microbial community and provides metabolites that influence the host physiology. Dietary patterns, including macronutrient balance and feeding/fasting cycles which may be manipulated with dietary regimens based on caloric restriction periods, influence the gut homeostasis through its impact on the microbial ecosystem. Along the same line, prebiotic and probiotic ingredients and additives in foods, as well as the degree of food processing have consequences on gut microbiota and the related immune and metabolic response of the human host. Acquiring knowledge of these aspects, especially through an -omics-integral approach, might provide the basis for personalized nutritional interventions directed to avoid dysbiosis and contribute to the prevention of major chronic degenerative diseases. Despite vast scientific evidence supporting the relationship between dietary factors and gut microbiota composition and function, the underlying mechanisms and their potential impact are far from clear. There is a lack of well-designed longitudinal studies performed in target population groups whose dietary patterns can be particularly relevant for their future health, as is the case in infants, pregnant women, or athletes.

14 July 2004 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
EREsther Nova Rebato
Esther Nova Rebato
AAAlberto Alvarez-Barrientos
Alberto Alvarez-Barrientos
AMAscensión Marcos
Ascensión Marcos
Julia WarnbergJulia Warnberg
Julia Warnberg
SGSonia Gómez-Martínez
Sonia Gómez-Martínez
JCJosé M. Cobo
José M. Cobo

18 April 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
SCSusana del Pozo de La Calle
Susana del Pozo de La Calle
SGSonia Gómez-Martínez
Sonia Gómez-Martínez
LPLigia Esperanza Díaz Prieto
Ligia Esperanza Díaz Prieto
EREsther Nova Rebato
Esther Nova Rebato
RURafael Urrialde
Rafael Urrialde
Ascensión MarcosAscensión Marcos
Ascensión Marcos
Artificial sweeteners are additives widely used in our diet. Although there is no consensus, current evidence indicates that sucralose and saccharin could influence the gut microbiota. The aim of this study was to analyze the existing scientific evidence on the effects of saccharin and sucralose consumption on gut microbiota in humans. Different databases were used with the following search terms: sweeteners, non-caloric-sweeteners, sucralose, splenda, saccharin, sugartwin, sweet’n low, microbiota, gut microbiota, humans, animal model, mice, rats, and/or in vitro studies. In vitro and animal model studies indicate a dose-dependent relationship between the intake of both sweeteners and gut microbiota affecting both diversity and composition. In humans, long-term study suggests the existence of a positive correlation between sweetener consumption and some bacterial groups; however, most short-term interventions with saccharin and sucralose, in amounts below the ADI, found no significant effect on those groups, but there seems to be a different basal microbiota-dependent response of metabolic markers. Although studies in vitro and in animal models seem to relate saccharin and sucralose consumption to changes in the gut microbiota, more long-term studies are needed in humans considering the basal microbiota of participants and their dietary and lifestyle habits in all population groups. Toxicological and basal gut microbiota effects must be included as relevant factors to evaluate food safety and nutritional consequences of non-calorie sweeteners. In humans, doses, duration of interventions, and number of subjects included in the studies are key factors to interpret the results.

10 July 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
EREsther Nova Rebato
Esther Nova Rebato
NUNOEMI REDONDO USEROS
NOEMI REDONDO USEROS
RMRosa M. Martínez
Rosa M. Martínez
SGSonia Gómez-Martínez
Sonia Gómez-Martínez
LPLigia Esperanza Díaz Prieto
Ligia Esperanza Díaz Prieto
Ascensión MarcosAscensión Marcos
Ascensión Marcos
Moringa oleifera (MO) is a multipurpose plant consumed as food and known for its medicinal uses, among others. Leaves, seeds and pods are the main parts used as food or food supplements. Nutritionally rich and with a high polyphenol content in the form of phenolic acids, flavonoids and glucosinolates, MO has been shown to exert numerous in vitro activities and in vivo effects, including hypoglycemic activity. A systematic search was carried out in the PubMed database and reference lists on the effects of MO on glucose metabolism. Thirty-three animal studies and eight human studies were included. Water and organic solvent extracts of leaves and, secondly, seeds, have been extensively assayed in animal models, showing the hypoglycemic effect, both under acute conditions and in long-term administrations and also prevention of other metabolic changes and complications associated to the hyperglycemic status. In humans, clinical trials are scarce, with variable designs and testing mainly dry leaf powder alone or mixed with other foods or MO aqueous preparations. Although the reported results are encouraging, especially those from postprandial studies, more human studies are certainly needed with more stringent inclusion criteria and a sufficient number of diabetic or prediabetic subjects. Moreover, trying to quantify the bioactive substances administered with the experimental material tested would facilitate comparison between studies.